Bernstein Keeps Outperform on Eli Lilly as GLP-1 Market Faces Novel Disruption
Bernstein SocGen Group has reaffirmed an Outperform rating and a $1,300 price target on Eli Lilly (LLY) amid concerns that a low-cost, telehealth-driven semaglutide pill could reshape both oral and injectable GLP-1 markets. The firm flagged regulatory ambiguity around compounding practices and outlined specific developments to watch, while Eli Lill…